EU blesses PML risk info for Tysabri label; Congress scolds FDA on recall tracking;

@FiercePharma:  AZ announces $1.8B dental-unit sale. Article | Follow @FiercePharma

> Biogen Idec and Elan have received European approval to include information on the Tysabri label about a risk factor for a serious brain disease. News

> Congressional auditors have faulted U.S. health regulators for failing to track unsafe medical devices after they are recalled, opening the door to further risks to patients. Story

> Watson Pharmaceuticals is set to expand Watson Laboratories' R&D and manufacturing facility in Salt Lake City, UT, with a $44 million investment. Report

> Six Indian drugmakers are set to enter the U.S. generic market for generic Levaquin (levofloxacin), an antibiotic approved for treating bacterial infections, including Aurobindo, Dr Reddy's, Glenmark, Lupin, Torrent and Wockhardt. Article

> Beiersdorf management board member Markus Pinger will become chief executive of Europe's largest drugs distributor Celesio from Aug. 15. Item

> Drugstore chain Brazil Pharma and shareholders priced on Wednesday an initial public offering aimed at funding acquisitions, opening new stores and new product development for the store brand. Piece

Biotech News

@FierceBiotech: Sen. Brown accuses an arbitrary FDA of "crushing" biotechs. News | Follow @FierceBiotech

> Apixaban bests warfarin in head-to-head study. Story 

> Diamyd ends late-stage study of diabetes-prevention drug. Report 

Vaccines News

> ImmunoCellular gains brain cancer vax patent. Article

> Protein could lead to better TB vaccine. News 

> Univ of Leeds cancer vax approach shows promise in study. Story 

> Researchers target weakness in HIV protein. Item

Manufacturing News

> Vax maker CSL hit with FDA warning. Article

> ICH hits milestone: Q11 draft posted for comments. Item 

> Masked informant leads fakes raid in Nigeria. News 

> Abbott diabetes gear lost in cargo theft. Article 

> Lonza adds early-phase bio-production service. Report 

> Abbott delays pink slips due to product demand. Story 

And Finally... Self-conscious about your age? Careful where you spit. Report

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.